{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:52:08Z","timestamp":1754160728937,"version":"3.41.2"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We report a case of a 65-year-old Japanese woman with low-risk myelodysplastic syndrome (MDS) on hemodialysis who achieved transfusion independence for over eight years with combined epoetin beta pegol (continuous erythropoietin receptor activator, CERA) and roxadustat. Transfusion-dependent since 2008, she showed a temporary response to darbepoetin and CERA, initiated in August 2016. Roxadustat was added in January 2020, leading to sustained transfusion independence. No serious adverse events, such as progression to acute leukemia or clinically significant thyroid dysfunction, were observed during this period.<\/jats:p>","DOI":"10.1093\/omcr\/omaf092","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:47:39Z","timestamp":1752504459000},"source":"Crossref","is-referenced-by-count":0,"title":["Over eight years of transfusion independence with continuous erythropoietin receptor activator and Roxadustat in transfusion-dependent low-risk myelodysplastic syndrome"],"prefix":"10.1093","volume":"2025","author":[{"given":"Tatsuyoshi","family":"Ikenoue","sequence":"first","affiliation":[{"name":"Data Science and AI Innovation Research Promotion Center, Shiga University , 1-1-1 Baba, Hikone, Shiga 522-8522 ,","place":["JAPAN"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Furumatsu","sequence":"additional","affiliation":[{"name":"Nephrology, Hirano Keijin Clinic , 3-2-20 Nagayoshi-Nagahara-Higashi, Hirano, Osaka 547-0013 ,","place":["JAPAN"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Nephrology, Hirano Keijin Clinic , 3-2-20 Nagayoshi-Nagahara-Higashi, Hirano, Osaka 547-0013 ,","place":["JAPAN"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"2025072710513978000_ref1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Greenberg","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"2025072710513978000_ref2","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1056\/NEJMp048266","article-title":"Myelodysplastic syndromes--coping with ineffective hematopoiesis","volume":"352","author":"Cazzola","year":"2005","journal-title":"N Engl J Med"},{"key":"2025072710513978000_ref3","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/leu.2017.192","article-title":"A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes","volume":"31","author":"Platzbecker","year":"2017","journal-title":"Leukemia"},{"key":"2025072710513978000_ref4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1681\/ASN.2012080855","article-title":"Mechanisms of hypoxia responses in renal tissue","volume":"24","author":"Haase","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2025072710513978000_ref5","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 Rockies study","volume":"33","author":"Fishbane","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025072710513978000_ref6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s13256-017-1468-z","article-title":"Epoetin \u03b2 pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report","volume":"11","author":"Ikenoue","year":"2017","journal-title":"J Med Case Rep"},{"key":"2025072710513978000_ref7","doi-asserted-by":"publisher","first-page":"omab026","DOI":"10.1093\/omcr\/omab026","article-title":"Transfusion-dependent anaemia treatment using continuous erythropoietin receptor activator (epoetin \u03b2 pegol) and roxadustat after darbepoetin treatment failure in low-risk myelodysplastic syndrome: a case report","volume":"2021","author":"Ikenoue","year":"2021","journal-title":"Oxf Med Case Rep"},{"key":"2025072710513978000_ref8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ajh.26397","article-title":"Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: open-label, dose-selection, lead-in stage of a phase 3 study","volume":"97","author":"Henry","year":"2022","journal-title":"Am J Hematol"},{"key":"2025072710513978000_ref9","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/ajh.27410","article-title":"Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: Matterhorn phase 3, double-blind, randomized controlled trial","volume":"99","author":"Mittelman","year":"2024","journal-title":"Am J Hematol"},{"key":"2025072710513978000_ref10","doi-asserted-by":"publisher","first-page":"2410375","DOI":"10.1080\/0886022X.2024.2410375","article-title":"Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study","volume":"46","author":"Otsuka","year":"2024","journal-title":"Ren Fail"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2025\/7\/omaf092\/63748836\/omaf092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2025\/7\/omaf092\/63748836\/omaf092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T14:51:44Z","timestamp":1753627904000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omaf092\/8200179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,14]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omaf092","relation":{},"ISSN":["2053-8855"],"issn-type":[{"type":"electronic","value":"2053-8855"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]},"article-number":"omaf092"}}